Reuters logo
BRIEF-Zealand and Helsinn say elsiglutide enters Phase IIB development
February 5, 2015 / 11:10 AM / 3 years ago

BRIEF-Zealand and Helsinn say elsiglutide enters Phase IIB development

Feb 5 (Reuters) - Zealand Pharma A/S :

* Zealand announces that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below